Company news

Cereno Scientific AB news in 2026

Cereno Scientific AB's news releases, calls and decks from 2026, newest first.

View company

Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program

March 31, 2026

Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD

March 17, 2026

Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease

February 4, 2026

Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases

January 14, 2026

Decks in 2026